🔎 Trials Near Me

Home › T-Cell Lymphoma › New York

T-Cell Lymphoma clinical trials in New York

15 studies for T-Cell Lymphoma are looking for participants at sites in New York.

Cities in New York

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • and 5 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04803201

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

  • Icahn School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • Weill Cornell Medicine, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

  • Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05010005

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

  • Rochester Skin Lymphoma Medical Group. PLLC, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06854653

CD4CAR for CD4+ Leukemia and Lymphoma

  • Albert Einstein Health Network, New York
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jun 24, 2026 · NCT03829540

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

  • Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 16, 2026 · NCT05463263

A Registry for People With T-cell Lymphoma

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Weill Cornell Medical Center (Data Collection Only), New York
  • and 2 more
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

  • Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT05996185

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

  • Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2025 · NCT06420089

Tissue Repository: CTCL Collection Protocol

  • Columbia University Irving Medical Center, New York
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT02840747

MB-105 in Patients With CD5 Positive T-cell Lymphoma

  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 3, 2025 · NCT06534060

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

  • Columbia University, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital New York-Presbyterian, New York
  • Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.